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ABSTRACT
Temsirolimus 175mg once-weekly for 3 weeks, followed by 75mg once-weekly intravenously
dosed (175/75mg) is approved in the European Union for treatment of relapsed/refractory mantle
cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety
could be achieved with 75mg without 175mg loading doses (ClinicaTrials.gov: NCT01180049).
Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75mg
(n¼ 47) or 75mg (n¼ 42). Treatment continued until objective disease progression. Primary end-
point: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and
adverse events (AEs). Median PFS was 4.3 versus 4.5 months (hazard ratio [HR] 0.731; 80% confi-
dence interval [CI], 0.520–1.027), and median OS 18.7 versus 11.0 months (HR 0.681; 80% CI,
0.472–0.982) with 175/75mg versus 75mg. There were fewer patients with serious AEs, dose
reduction, or death with 175/75mg (57.4%, 48.9%, and 48.9%) versus 75mg (73.8%, 64.3%, and
65.1%). Temsirolimus 175/75mg remains the preferred dosing regimen for relapsed/refractory MCL.
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Introduction
Mantle cell lymphoma (MCL) is a relatively rare subtype
of non-Hodgkin lymphoma, diagnosed in 6–8% of all
cases, predominantly in males aged >60 years [1–3].
MCL usually has an aggressive clinical course: although
a growth pattern resembles low-grade lymphoma, it
develops resistance to conventional chemotherapy rela-
tively early and is considered incurable with conven-
tional chemotherapy [1,4]. The majority of individuals
have intermediate-high-risk or high-risk disease;
60–70% of patients with MCL have advanced disease
(Ann Arbor stage IV) at the time of initial diagnosis [5–7].
Temsirolimus, a selective inhibitor of mTOR, is
approved in the European Union for the treatment of
adult patients with relapsed and/or refractory MCL at
an intravenous loading dose of 175mg once-weekly for
the first 3 weeks followed by 75mg intravenously once-
weekly (temsirolimus 175/75mg) [8]. This approval was
based on an overall positive benefit-risk assessment
demonstrated in the pivotal phase III study where
temsirolimus 175/75mg prolonged progression-free
survival (PFS) significantly over investigator’s choice
(median: 4.8 versus 1.9 months; hazard ratio [HR] 0.44;
97.5% confidence interval [CI], 0.25–0.78; p¼ .0009) [8].
Despite the improvement in PFS versus inves-
tigator’s choice, the 175/75-mg dose regimen was
associated with higher incidence of grade 3
adverse events (AEs) and serious AEs relative to
investigator’s choice [8]. However, as the initial load-
ing dose had been selected based on individual tol-
erability rather than on a precise pharmacokinetic
modeling, it was questioned whether this intensive
and potentially more toxic treatment phase is
required or could be skipped, thereby improving tol-
erability without compromising efficacy. To this
intent, a phase IV study was conducted to explore
whether similar efficacy but improved safety could
be achieved with an alternative temsirolimus dosing
regimen that removes the first three loading doses
of temsirolimus 175mg in the treatment of patients
with relapsed/refractory MCL.
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Methods
Patients
Key inclusion criteria included age 18 years, histolog-
ically confirmed refractory and/or relapsed MCL, immu-
nophenotype, and cyclin D1 analysis after receiving
2–7 prior therapies. Prior treatment must have
included an alkylating agent and an anthracycline and
rituximab, individually or in combination, and could
have included hematopoietic stem cell transplant, i.e.
induction plus consolidation plus maintenance.
Patients had to have measurable disease, Eastern
Cooperative Oncology Group performance status 0–2,
and adequate organ and marrow function. Key exclu-
sion criteria included having active central nervous
system metastases (except for clinically stable brain
metastases), and any prior history of noninfectious
interstitial pneumonitis/interstitial lung disease.
Patients were also excluded if they received any of the
following treatments: chemotherapy, radiotherapy,
immunotherapy, or major surgery 3 weeks prior.
Study design
This was a phase IV, multicenter, randomized, open-
label study of temsirolimus in patients with relapsed,
refractory MCL (ClinicaTrials.gov: NCT01180049). The
study was conducted in 16 countries: Australia,
Belgium, Bulgaria, Czech Republic, France, Germany,
Hong Kong, Hungary, Italy, Netherlands, Poland,
Republic of Korea, Romania, Russian Federation, Serbia,
and USA. The first patient was enrolled on 10 March
2011.
The study protocol, amendments, and informed
consent forms were reviewed and approved by the
institutional review board or independent ethics com-
mittee at each study center. The study was conducted
in accordance with the protocol, International
Conference on Harmonization Good Clinical Practice
guidelines, and applicable local regulatory require-
ments and laws. Informed consent was obtained from
each patient prior to study initiation.
Procedures
In this study, previously heavily treated (2–7 lines of
prior therapy) patients with relapsed/refractory MCL
were stratified by the histologic subtype (blastoid ver-
sus nonblastoid versus unknown histology) and
randomized (1:1) to receive intravenous temsirolimus
175/75mg or 75mg weekly. Due to limited sample
size and the expectation of strata sizes being signifi-
cantly disproportioned, the primary analysis was
not stratified. Treatment continued until objective dis-
ease progression according to Cheson Criteria (version
1999) [9], provided patients were tolerating treatment.
Temsirolimus dose reductions to 75mg (in the 175/75-
mg group), 50mg, 25mg, and 15mg were permitted
on the basis of individual tolerability. Patients with-
drawn from the study were not replaced, irrespective
of the reason for withdrawal.
The study included a 4-week screening phase, a
treatment phase, and a long-term follow-up phase.
‘On-treatment’ was defined as the time from the first
dose until 30 days after the last dose of temsirolimus.
‘On-study’ ranged from the time of randomization
until patient was reported off-study due to death,
withdrawal of consent, or lost to follow-up. An exter-
nal data monitoring committee (EDMC) was respon-
sible for routine monitoring of the safety of patients in
the study according to the EDMC Charter.
Assessments
Efficacy was assessed using the modified International
Working Group response criteria (Cheson Criteria, ver-
sion 1999), which were standard at the time of study
initiation [9]. Objective tumor responses were deter-
mined by computed tomography scans, as well as clin-
ical information, including B-symptom evaluation,
physical examination, Eastern Cooperative Oncology
Group performance status, assessment of liver and
spleen, laboratory assessments such as bone marrow
biopsies and/or aspirates, biochemical markers of dis-
ease activity (i.e. lactate dehydrogenase [LDH]), and
hematology results.
Safety assessment included AEs classified by type,
incidence, severity, seriousness, relationship to the
study drug, and laboratory abnormalities (severity
graded by the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0).
Any serious AEs beyond 30 days after the last dose of
study drug considered at least possibly treatment-
related were reported. AEs of interest (infection- and
bleeding-related) were also assessed on an ongoing
basis while on study treatment. Other safety assess-
ments included physical examination and vital signs,
12-lead electrocardiogram, and laboratory test evalua-
tions. Survival follow-up was conducted every three
months from the time of the last temsirolimus infusion
until death or withdrawal of informed consent.
Statistical analyses
Sample size was based on clinical considerations.
The primary endpoint was PFS (by an independent
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assessor), defined as the time from randomization to
progressive disease or death, censored at the last
adequate tumor assessment prior to initiation of new
anticancer therapy. Secondary endpoints included
overall survival (OS), objective response rate (ORR),
Investigator-assessed PFS, and safety, with a particular
focus on bleeding- and infection-related AEs. Other
exploratory endpoints included duration of response
and time to tumor progression (TTP).
The intent-to-treat (ITT) population included all
patients randomized to receive temsirolimus and was
the primary population for evaluating all efficacy end-
points and patient characteristics. Safety analyses were
conducted on the safety population, which included
all patients receiving 1 dose of temsirolimus.
Analyses were conducted after all patients had at least
one-year observation or were off study.
For all time-to-event endpoints, HRs and their
80%CIs were estimated using an unstratified Cox
regression model. Because there were no formal statis-
tical hypotheses for this study, p-values have not been
reported. The median time-to-event was also esti-
mated using the Kaplan–Meier method with two-sided
80%CIs reported for each treatment group. ORR and
its exact 80%CI were estimated for each treatment
group. The difference in ORR between the two treat-
ment groups was estimated along with exact 80%CI.
Safety was evaluated by comparing the incidence of
AEs between the two treatment groups.
Results
Patients and treatment
Ninety heavily pretreated patients out of the initially
planned 100 patients were randomized and consti-
tuted the ITT population; 47 patients in the 175/75-mg
group and 43 patients in the 75-mg group. All the 47
(100%) patients in the 75/75-mg group and 42 (97.7%)
patients in the 75-mg group received allocated treat-
ment, and constituted the safety population. One
(2.3%) patient in the 75-mg group was randomized
but not treated. There was a higher percentage of
females and patients with five or more prior therapies
in the 175/75-mg group. Patient demographics and
baseline disease characteristics are shown in Table 1.
At the cutoff date for analysis (12 November 2015),
39 (83.0%) patients in temsirolimus 175/75-mg group
and 41 (95.3%) patients in temsirolimus 75-mg group
discontinued treatment; the primary reason was
objective disease progression in 53.8% versus 56.1% of
patients, respectively. Median duration of treatment
was comparable in the two temsirolimus groups
(3.2 versus 3.1 months, with 175/75mg versus 75mg,
respectively).
The median (range) cumulative exposure to study
drug over the entire treatment period was 900
(175–12,350) mg in the 175/75-mg group and 500
(75–3750) mg in the 75-mg group. The median (range)
number of doses received during the entire study was
10.0 (1–164) and 9.0 (1–55), respectively. The median
(range) number of doses received during the first
three weeks was 2.0 (1–3) in both groups (Table 2).
Efficacy
The median independently assessed PFS (80%CI) was
4.3 (3.3–6.4) months in the 175/75-mg group versus
Table 1. Patient demographics and baseline characteristics.
Temsirolimus dose group
Characteristic 175/75mg n¼ 47 75mg n¼ 43 Total N¼ 90
Age, years
Mean (SD) 67.0 (8.49) 66.3 (8.47) 66.6 (8.44)
Median (range) 66.0 (47–85) 67.0 (47–86) 67.0 (47–86)
<65, n (%) 21 (44.7) 17 (39.5) 38 (42.2)
65, n (%) 26 (55.3) 26 (60.5) 52 (57.8)
Sex, n (%)
Male 34 (72.3) 36 (83.7) 70 (77.8)
Female 13 (27.7) 7 (16.3) 20 (22.2)
Race, n (%)
White 45 (95.7) 39 (90.7) 84 (93.3)
Asian 2 (4.3) 4 (9.3) 6 (6.7)
Histologic subtype of MCL, n (%)
Blastoid 7 (14.9) 7 (16.3) 14 (15.6)
Nonblastoid 32 (68.1) 30 (69.8) 62 (68.9)
Unknown 8 (17.0) 6 (14.0) 14 (15.6)
Involved disease sites, n (%)
Lymph node 36 (76.6) 38 (88.4) 74 (82.2)
Liver 1 (2.1) 2 (4.7) 3 (3.3)
Spleen 5 (10.6) 3 (7.0) 8 (8.9)
Other 20 (42.6) 17 (39.5) 37 (41.1)
Not reported 5 (10.6) 1 (2.3) 6 (6.7)
Stage at initial diagnosis, n (%)
I 2 (4.3) 2 (4.7) 4 (4.4)
II 1 (2.1) 2 (4.7) 3 (3.3)
III 6 (12.8) 8 (18.6) 14 (15.6)
IV 35 (74.5) 25 (58.1) 60 (66.7)
Other 0 1 (2.3) 1 (1.1)
Unknown 3 (6.4) 5 (11.6) 8 (8.9)
Bone marrow involvement, n (%)
Positive 22 (46.8) 23 (53.5) 45 (50.0)
Negative 21 (44.7) 18 (41.9) 39 (43.3)
Intermediate 1 (2.1) 0 1 (1.1)
Not done 3 (6.4) 2 (4.7) 5 (5.6)
ECOG performance status, n (%)
0 25 (53.2) 20 (46.5) 45 (50.0)
1 17 (36.2) 16 (37.2) 33 (36.7)
2 5 (10.6) 7 (16.3) 12 (13.3)
Number of prior systemic therapies, n (%)
1 0 1 (2.3) 1 (1.1)
2–3 26 (55.3) 29 (67.4) 55 (61.1)
4–5 15 (31.9) 13 (30.2) 28 (31.1)
>5 6 (12.8) 0 6 (6.7)
175/75mg: temsirolimus 175mg intravenous dose once-weekly for first 3
weeks, followed by 75mg intravenous once-weekly; 75mg: temsirolimus
75mg intravenous once-weekly;
ECOG: Eastern Cooperative Oncology Group; MCL: mantle cell lymphoma;
SD: standard deviation.
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4.5 (2.7–4.9) months in the 75-mg group (HR 0.731;
80%CI, 0.520–1.027; Figure 1). Although there was no
difference in the median PFS, the 75% quartile PFS
(80%CI) differed substantially between the 175/75-mg
and 75-mg treatment groups (14.9 [8.4–16.4] months
versus 7.8 [6.5–11.7] months, respectively). The median
investigator-assessed PFS was 4.7 (2.7–8.3) months ver-
sus 3.9 (2.8–4.7) months, respectively (HR 0.646; 80%CI,
0.453–0.922; Figure 1), supporting the conclusion that
the HR favored the temsirolimus 175/75-mg group
with a point estimate <1.
The discordance between PFS in the number of
patients deemed as having progressed by the inde-
pendent review but alive and progression-free by the
investigator was eight (17.0%) for the 175/75-mg and
three (7.0%) for the 75-mg groups. Similarly, the dis-
cordance between PFS in the number of patients
deemed as having progressed but alive by the investi-
gator versus progression-free by the independent
review was one (2.1%) for the 175/75-mg group and
five (11.6%) for the 75-mg group.
Univariate analysis of PFS based on independent
assessment by age group, ethnic origin, gender, and
geographic region did not show statistical significance
for any of these factors. As none of the factors in the
univariate analysis were statistically significant, a multi-
variate analysis was not conducted.
The ORR (80%CI) was 27.7% (19.1–37.7%) in the
175/75-mg group versus 20.9% (13.0–31.0%) in the
75-mg group. The ORR results based on the inves-
tigator’s assessment were in line with the independent
review results (Table 3).
The median duration of response was comparable
in both treatment groups (9.0 versus 8.7 months,
175/75 versus 75mg, respectively). The median TTP
(80%CI) was 6.4 (4.4–10.1) months versus 4.8 (3.9–6.5)
months, respectively (HR 0.613; 80%CI, 0.415–0.905).
The TTP results based on the investigator’s assessment
were in line with the independent review results.
As of the data cutoff date, 23 (48.9%) patients in
the 175/75-mg group and 28 (65.1%) patients in the
75-mg group had died. The median OS (80%CI) was
18.7 (7.5–48.2) months in the 175/75-mg group com-
pared with 11.0 (6.3–16.2) months in 75-mg group
(HR 0.681; 80%CI, 0.472–0.982; Figure 2). The 75%
quartile OS (80%CI) was 48.2 months with temsiroli-
mus 175/75mg compared with 19.8 months with tem-
sirolimus 75mg.
Follow-up therapy
A total of 17 patients in each treatment group (36.2%
in the 175/75-mg group and 39.5% in the 75-mg
group) received 1 systemic therapy after the last
dose of temsirolimus. About 60% of all patients did
not report any follow-up systemic therapies. The most
common systemic follow-up therapy was ibrutinib by
14.9% of patients in the 175/75-mg group and 18.6%
of patients in the 75-mg group. The types and number
of regimens were generally similar across both treat-
ment groups with the exception of rituximab, which
was given at a higher frequency in the 175/75-mg
group compared with the 75-mg group (21.3% versus
4.7%, respectively). The number of patients who had
radiation therapy and/or surgery after temsirolimus
was also well balanced across treatment groups, taking
into account that few (<5%) patients had radiation
therapy or surgery after temsirolimus treatment ended.
Table 2. Drug exposure during the study – safety population.
Temsirolimus dose group
175/75mg n¼ 47 75mg n¼ 42 Total N¼ 89
Total dose received during the entire period, mg
Mean (SD) 1638.9 (2010.6) 843.0 (748.8) 1263.3 (1591.9)
Median (range) 900 (175–12350) 500 (75–3750) 650 (75–12350)
Number of doses received during the entire period
Mean (SD) 24.9 (35.3) 14.9 (12.9) 20.2 (27.4)
Median (range) 10.0 (1–164) 9.0 (1–55) 10.0 (1–164)
Dose intensity, Weeks 1–3, mg/week
Mean (SD) 125.0 (43.6) 57.5 (17.6) 93.2 (47.8)
Median (range) 116.7 (53.3–183.8) 53.9 (25.0–78.8) 75.0 (25.0–183.8)
Number of doses received, Weeks 1–3
Mean (SD) 2.1 (0.7) 2.3 (0.7) 2.2 (0.7)
Median (range) 2.0 (1–3) 2.0 (1–3) 2.0 (1–3)
Patients with dose delay, Weeks 1–3, n (%) 28 (59.6) 22 (52.4) 50 (56.2)
Patients with dose reduction, Weeks 1–3, n (%) 7 (14.9) 2 (4.8) 9 (10.1)
Dose intensity, Weeks >3, mg/week
Mean (SD) 52.1 (19.5) 44.1 (18.5) 48.3 (19.3)
Median (range) 58.4 (13.1–77.2) 41.3 (17.7–75.8) 49.0 (13.1–77.2)
175/75mg: temsirolimus 175mg intravenous dose once-weekly for first 3 weeks, followed by 75mg intravenous once-weekly; 75mg: temsirolimus 75mg
intravenous once-weekly; SD: standard deviation.
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Safety
Overall, the safety profile was comparable in both
treatment groups, although the number of patients
with serious AEs, dose reductions, or death was lower
in the 175/75-mg versus the 75-mg group, and the
number of treatment discontinuations due to AEs was
higher with temsirolimus 175/75mg compared with
75mg (Table 4). Median (range) time to treatment dis-
continuation due to AEs was 8.2 (0.1–37.4) weeks in
the 175/75-mg group compared with 6.1 (2.1–42.7)
Table 3. Best overall response – intent-to-treat population.
Independent assessment Investigator assessment
Temsirolimus dose group Temsirolimus dose group
175/75mg n¼ 47 75mg n¼ 43 175/75mg n¼ 47 75mg n¼ 43
Complete response, n (%) 2 (4.3) 1 (2.3) 2 (4.3) 0
Partial response, n (%) 11 (23.4) 8 (18.6) 13 (27.7) 8 (18.6)
Stable disease, n (%) 20 (42.6) 22 (51.2) 17 (36.2) 25 (58.1)
Progressive disease, n (%) 7 (14.9) 7 (16.3) 10 (21.3) 7 (16.3)
Non-evaluable, n (%) 7 (14.9) 5 (11.6) 5 (10.6) 3 (7.0)
Objective response rate (CRþ PR), n (%) 13 (27.7) 9 (20.9) 15 (31.9) 8 (18.6)
80% exact CI 19.1–37.7 13.0–31.0 22.9–42.2 11.1–28.5
Difference 175/75 versus 75mg, % (80% CI) – 6.7 (6.9, 20.3) – 13.3 (0.4, 26.7)
175/75mg: temsirolimus 175mg intravenous dose once-weekly for first 3 weeks, followed by 75mg intravenous once-weekly; 75mg: temsirolimus 75mg
intravenous once-weekly; CI: confidence interval; CR: complete response; PR: partial response.
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Figure 1. Kaplan–Meier plot of progression-free survival based on independent (A) or investigator (B) assessment: Intent-to-treat
population. 175/75mg: temsirolimus 175mg intravenous dose once-weekly for first 3 weeks, followed by 75mg intravenous once-
weekly; 75mg: temsirolimus 75mg intravenous once-weekly.
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weeks in the 75-mg group. The most common reasons
for permanent discontinuation due to AE were dys-
pnea (n¼ 2: one within the first three weeks and one
from the forth week onwards, both in the 175/75-mg
group) and pneumonia (n¼ 2: one within the first
three weeks in the 175/75-mg group and one from
the forth week onwards in the 75-mg group). Other
AEs leading to discontinuation included hydrothorax,
pulmonary toxicity, respiratory failure, pneumocystis
jiroveci pneumonia, headache, neuralgia, myocardial
infarction, rectal hemorrhage, hypertriglyceridemia,
and skin ulcer (n¼ 1 each). Two of the nine patients in
the 175/75-mg group who discontinued due to AEs
had died (pneumonia and disease progression).
Treatment-emergent AEs were reported in 46
(97.9%) patients in the 175/75-mg group and for all
patients in the 75-mg group (Table 5). Common
(>10%) grade3, all-causality, treatment-emergent
AEs in the 175/75-mg and 75-mg groups, respectively,
were thrombocytopenia (46.8% versus 38.1%), neutro-
penia (25.5% versus 21.4%), and pneumonia (10.6%
versus 19.0%) (Table 5).
Treatment-emergent, bleeding-related AEs of
grade2 in the first three weeks occurred in three
(6.4%) patients in the 175/75-mg group and one
(2.4%) patient in the 75-mg group compared with four
(9.5%) and 0 patients, respectively, from the fourth
week onwards. The most common treatment-emer-
gent, bleeding-related AEs were epistaxis and ecchym-
osis in both treatment groups. Only one grade 3 AE of
epistaxis that was not related to temsirolimus was
reported in the 175/75-mg group, and no grade 3
events were reported in the 75-mg group. Two
patients in the 175/75-mg group and one patient in
the 75-mg group had treatment-emergent, bleeding-
related AEs that resulted in a temporary stop in study
drug; no patients in either group had a treatment-
emergent, bleeding-related AE that led to treatment
discontinuation. One treatment-emergent AE of epi-
staxis in the 175/75-mg group was assessed to be a
serious AE.
Treatment-emergent infection events were compar-
able across both treatment groups (25.5% of patients
in the 175/75-mg group versus 23.8% in the 75-mg
group). Pneumonia was the most commonly occurring
treatment-emergent, infection-related grade2 AE
(12.8% of patients in the 175/75-mg group and 19.0%
in the 75-mg group). The number of grade3 events
was lower in the 175/75-mg group (14.9%) versus the
75-mg group (21.4%). Treatment-emergent infection
events leading to discontinuation were reported for
one patient in each group.
Of the 51 deaths reported during the study, the
majority of patients died28 days after last dosing.
None of the deaths were considered treatment-related
and most were due to disease progression (n¼ 44).
Other causes of death in the 175/75-mg group
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Figure 2. Kaplan–Meier curve of overall survival: Intent-to-treat population. 175/75mg: temsirolimus 175mg intravenous dose
once-weekly for first 3 weeks, followed by 75mg intravenous once-weekly; 75mg: temsirolimus 75mg intravenous once-weekly.
Table 4. Treatment-emergent, all-causality adverse events
over entire treatment duration – safety population.
Temsirolimus dose group
n (%)
175/75mg
n¼ 47
75mg
n¼ 42
Any adverse event 46 (97.9) 42 (100.0)
Grade 3 adverse event 40 (85.1) 35 (83.3)
Serious adverse event 27 (57.4) 31 (73.8)
Adverse event leading to dose delay 41 (87.2) 39 (92.9)
Adverse event leading to dose reduction 23 (48.9) 27 (64.3)
Adverse event leading to discontinuation 9 (19.1) 6 (14.3)
Deaths 11 (23.4) 12 (28. 6)
175/75mg: temsirolimus 175mg intravenous dose once-weekly for first
3 weeks, followed by 75mg intravenous once-weekly; 75mg: temsiroli-
mus 75mg intravenous once-weekly.
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included pneumonia assessed as unrelated to study
drug in one (2.1%) patient who died within 28 days
after last dosing. In the 75-mg group, one (2.3%)
patient died prior to receiving the study drug; another
patient, for unknown reason, died within 28 days after
last dosing. One additional patient in the 75-mg group
died within 28 days of last dose of temsirolimus due
to cardiorespiratory failure. After 28 days of last dos-
ing, one patient in each group died due to unknown
reasons, and one (2.3%) patient in the 75-mg group
died due to cardiorespiratory failure.
Discussion
Patients with MCL typically develop chemo-resistance
during the course of the disease. Despite active treat-
ments for MCL, such as ibrutinib, bortezomib, lenalido-
mid, and temsirolimus, there is no standard treatment
for refractory MCL. The efficacy of temsirolimus in
heavily pretreated patients with MCL has been estab-
lished in a randomized clinical trial wherein temsiroli-
mus 175/75-mg regimen resulted in significant
improvements in PFS and ORR compared with the
investigator’s choice. However, there was a higher inci-
dence of grade 3 treatment-emergent AEs and a
greater number of AEs leading to dose reduction or
delay with temsirolimus 175/75 mg compared with the
investigator’s choice [8]. It had remained unanswered
whether the intensive induction in the 175/75-mg regi-
men would be beneficial or might be less effective,
and if tolerability would be reduced. Therefore, to
explore whether similar efficacy but improved safety
could be achieved in heavily pretreated patients with
relapsed/refractory MCL, we compared two dosing reg-
imens of temsirolimus: 175/75-mg versus a 75-mg
dosage.
The benefit-risk assessment for this study centered
on the fact that patients in the 175/75-mg group were
receiving a regimen that is already approved in
Europe for the treatment of relapsed and/or refractory
MCL. Patients in the 75-mg group received a dosage
regimen that did not include the three starting doses
of 175mg temsirolimus, but had the potential to be
safer than the 175/75-mg dosing schedule, while being
equally effective. A smaller study with only 29 patients
has shown efficacy with lower dose of temsirolimus
(25mg/week); however, these results were not con-
firmed in a phase III trial [10].
Overall, the primary efficacy endpoint of independ-
ently assessed PFS, the secondary efficacy endpoints
of ORR and OS, and other secondary endpoints,
favored the temsirolimus 175/75-mg treatment.
Although no formal statistical conclusions were made,
as the study was not powered to detect significant dif-
ferences between the study groups, the HRs for the
investigator-assessed PFS and OS were 0.646 and
0.681, respectively, and the 80%CI excluded 1, sug-
gesting a difference between the two groups. For the
endpoints of PFS and OS, the Kaplan–Meier curves
began to separate after the median time point in the
175/75-mg group and were in favor of the 175/75-mg
regimen (Figures 1 and 2). This suggests the initial
loading doses of temsirolimus 175mg contribute to
rapid disease control. The results for the primary end-
point of PFS were comparable to those observed in
the previous phase III study of temsirolimus, wherein
Table 5. Common treatment-emergent, all-causality adverse events experienced by 15% of patients – safety population.
Temsirolimus dose group
175/75mg n¼ 47 75mg n¼ 42 Total N¼ 89
Adverse event, n (%) All Grades Grade3 All Grades Grade3 All Grades Grade3
Any adverse event 46 (97.9) 40 (85.1) 42 (100.0) 35 (83.3) 88 (98.9) 75 (84.3)
Thrombocytopenia 32 (68.1) 22 (46.8) 24 (57.1) 16 (38.1) 56 (62.9) 38 (42.7)
Diarrhea 17 (36.2) 1 (2.1) 12 (28.6) 1 (2.4) 29 (32.6) 2 (2.2)
Neutropenia 16 (34.0) 12 (25.5) 11 (26.2) 9 (21.4) 27 (30.3) 21 (23.6)
Dyspnea 11 (23.4) 2 (4.3) 13 (31.0) 2 (4.8) 24 (27.0) 4 (4.5)
Fatigue 11 (23.4) 2 (4.3) 13 (31.0) 4 (9.5) 24 (27.0) 6 (6.7)
Pyrexia 15 (31.9) 3 (6.4) 9 (21.4) 3 (7.1) 24 (27.0) 6 (6.7)
Anemia 10 (21.3) 3 (6.4) 13 (31.0) 3 (7.1) 23 (25.8) 6 (6.7)
Epistaxis 13 (27.7) 1 (2.1) 8 (19.0) 0 21 (23.6) 1 (1.1)
Upper respiratory tract infection 8 (17.0) 2 (4.3) 11 (26.2) 1 (2.4) 19 (21.3) 3 (3.4)
Disease progression 9 (19.1) 9 (19.1) 9 (21.4) 9 (21.4) 18 (20.2) 18 (20.2)
Edema peripheral 8 (17.0) 0 8 (19.0) 1 (2.4) 16 (18.0) 1 (1.1)
Cough 7 (14.9) 0 8 (19.0) 0 15 (16.9) 0
Nausea 6 (12.8) 0 9 (21.4) 2 (4.8) 15 (16.9) 2 (2.2)
Pneumonia 6 (12.8) 5 (10.6) 9 (21.4) 8 (19.0) 15 (16.9) 13 (14.6)
Hypokalemia 6 (12.8) 2 (4.3) 8 (19.0) 2 (4.8) 14 (15.7) 4 (4.5)
Rash 8 (17.0) 0 6 (14.3) 1 (2.4) 14 (15.7) 1 (1. 1)
175/75mg: temsirolimus 175mg intravenous dose once-weekly for first 3 weeks, followed by 75mg intravenous once-weekly; 75mg: temsirolimus 75mg
intravenous once-weekly.
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median PFS with the 175/75-mg dose was 4.8 months
[8] compared with 4.3 months in the current phase IV
study. A longer median PFS (6.2 months) with temsiro-
limus 175/75 mg was achieved in the RAY study, prob-
ably because patients included in that study were not
as heavily pretreated [11]. ORR in patients receiving
175/75-mg temsirolimus treatment was also compar-
able between the phase III trial [8] and the current
phase IV study (22% and 27.7% of patients,
respectively).
In the current study, the overall safety profile
across the two treatment groups was comparable,
but there was a lower incidence of serious AEs, dose
reductions, and deaths in the 175/75-mg group ver-
sus the 75-mg group. These safety results are consist-
ent with the known safety profile of temsirolimus
[8,12]; no new safety signals were reported.
Furthermore, the most commonly occurring grade 3
AEs in this study (thrombocytopenia and neutropenia)
were similar to those reported in two recent studies
comparing ibrutinib versus temsirolimus [11] and
lenalidomide versus the investigator’s choice [13].
Early management of AEs, especially those leading to
discontinuation (e.g. dyspnea and pneumonia), is
essential to improving patient quality of life and
treatment outcome.
Bleeding- and infection-related AEs were of particu-
lar interest in this study as they are known to be asso-
ciated with temsirolimus and other mTOR inhibitors
[14,15]. The incidence of treatment-emergent, bleed-
ing-related AEs was higher in the 175/75-mg group
versus the 75-mg group, but not during the first 3
weeks of the study (when the loading dose was
administered) and the one grade 3 bleeding-related
AE was deemed not treatment-related. The incidence
of treatment-emergent, infection-related AEs was com-
parable between treatment groups.
The cumulative evidence across both efficacy and
safety measures demonstrated the 175/75-mg temsiro-
limus regimen was associated with a higher level of
efficacy and a similar safety profile compared with the
75-mg regimen. As PFS tended to be longer, more
patients remained on treatment and overall drug
exposure was higher in the 175/75-mg treatment
group. The continued use of the 175/75-mg regimen
is justified by the current analysis, especially as the ini-
tial phase III trial demonstrated a significant improve-
ment in PFS and ORR with this dosing regimen.
Importantly, an early de-escalation in dosage is not
associated with improved tolerability.
Treatment landscape has changed since the intro-
duction of temsirolimus within the algorithm of MCL
treatment and more treatment options are available
today. If and how other therapies work after expos-
ure to temsirolimus is of interest. Therefore, we con-
ducted a follow-up of patients who received other
treatments post temsirolimus and found the number
of patients who received additional systemic therapy
after temsirolimus treatment ended was well bal-
anced across both the 175/75-mg and 75-mg treat-
ment groups (36.2% versus 39.5%, respectively). Also,
the types and number of regimens were generally
similar across treatment groups, with the exception
of rituximab, which was prescribed more frequently
to patients in the 175/75-mg group compared with
the 75-mg group. Therefore, given that a small pro-
portion of patients receiving follow-up systemic can-
cer therapy after temsirolimus treatment was
generally comparable between treatment groups, we
concluded the OS results did not appear to be
impacted by post-study treatment for MCL.
The higher response rate and longer median PFS,
respectively, demonstrated with ibrutinib (72% and
14.6 months) [11] and lenalidomide (40% and 8.7
months) [13] in patients with MCL, and their oral
administration, would probably position them as a
preferable treatment before temsirolimus and other
mTOR inhibitors. Nonetheless, the PI3K/Akt/mTOR
pathway is an important therapeutic target in MCL
because it is consistently dysregulated and contributes
to MCL pathogenesis [16]. Inhibitors of the PI3K/Akt/
mTOR pathway, including temsirolimus, everolimus
and idelalisib have demonstrated clinical benefit in
relapsed/refractory MCL [8,17,18]. In our study, temsir-
olimus demonstrated clinical benefit in heavily pre-
treated patients with relapsed/refractory MCL. Because
none of these agents is curative as a single agent,
they should be investigated in combination with other
agents to enhance their activity. Indeed, several phase
I/II studies demonstrated high response rate with tem-
sirolimus in combination with rituximab and chemo-
therapy [19–21].
In conclusion, PFS, ORR, and OS favored the tem-
sirolimus 175/75-mg regimen over the 75-mg regi-
men, although no formal statistical conclusions were
made, as the study was not powered to detect sig-
nificant differences between study groups. The safety
profile in both study groups was comparable, but
there was a lower incidence of serious AEs, dose
reductions, and deaths in the 175/75-mg group.
Consequently, temsirolimus 175/75mg remains the
preferred dosing regimen for patients with relapsed/
refractory MCL and additional combination studies
should be investigated.
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